Por favor, use este identificador para citar o enlazar este ítem:
https://repositorio.uca.edu.ar/handle/123456789/1647
Título : | Melatonin therapy in patients with Alzheimer's disease | Autor : | Cardinali, Daniel Pedro Vigo, Daniel Eduardo Olivar, Natividad Vidal, María Florencia Brusco, Luis I. |
Palabras clave : | MELATONINA; ENFERMEDAD DE ALZHEIMER; ENVEJECIMIENTO; DETERIORO COGNITIVO LEVE; TRASTORNOS DE LA MEMORIA | Fecha de publicación : | 2014 | Editorial : | MDPI AG | Cita : | Cardinali, D. P., et al. Melatonin therapy in patients with Alzheimer's disease [en línea]. Antioxidants. 2014, 3. doi:10.3390/antiox3020245. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1647 | Resumen : | Abstract: Alzheimer’s disease (AD) is a major health problem and a growing recognition exists that efforts to prevent it must be undertaken by both governmental and non-governmental organizations. In this context, the pineal product, melatonin, has a promising significance because of its chronobiotic/cytoprotective properties potentially useful for a number of aspects of AD. One of the features of advancing age is the gradual decrease in circulating melatonin levels. A limited number of therapeutic trials have indicated that melatonin has a therapeutic value as a neuroprotective drug in the treatment of AD and minimal cognitive impairment (which may evolve to AD). Both in vitro and in vivo, melatonin prevented the neurodegeneration seen in experimental models of AD. For these effects to occur, doses of melatonin about two orders of magnitude higher than those required to affect sleep and circadian rhythmicity are needed. More recently, attention has been focused on the development of potent melatonin analogs with prolonged effects, which were employed in clinical trials in sleep-disturbed or depressed patients in doses considerably higher than those employed for melatonin. In view that the relative potencies of the analogs are higher than that of the natural compound, clinical trials employing melatonin in the range of 50–100 mg/day are urgently needed to assess its therapeutic validity in neurodegenerative disorders such as AD. | URI : | https://repositorio.uca.edu.ar/handle/123456789/1647 | ISSN : | 2076-3921 | Disciplina: | MEDICINA | DOI: | 10.3390/antiox3020245 | Derechos: | Acceso Abierto |
Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
melatonin-therapy-patients-alzheimer.pdf | 548,61 kB | Adobe PDF | Visualizar/Abrir |
Visualizaciones de página(s)
160
comprobado en 30-abr-2024
Descarga(s)
154
comprobado en 30-abr-2024
Google ScholarTM
Consultar
Altmetric
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons